Bolstered by a breakthrough drug designation at the FDA, Amgen is following through with a new drug application for its leukemia drug blinatumomab, hoping that promising Phase II data will be enough to push this program past the goal line on a greatly accelerated development schedule.

…read more

Source: Amgen pushes for early FDA OK of leukemia drug blinatumomab


0 No comments